Status of research on the application of melatonin in insomnia based on bibliometric visualization analysis and development trends.

Insomnia affects millions of people worldwide and disrupts quality of life. Researchers analyzed nearly 1,100 scientific studies published between 2015 and 2024 to understand how melatonin is being used to treat sleep problems. Melatonin is a hormone naturally produced by your body that helps regulate sleep-wake cycles, and it's also available as a supplement. This large review found that research on melatonin for insomnia has been steadily increasing over the past decade. Scientists have focused particularly on using melatonin to help three groups: children with sleep difficulties, older adults experiencing age-related insomnia, and people with neurological conditions that disrupt sleep. The studies show that melatonin is being investigated not just for basic insomnia, but also for sleep problems that occur alongside other health conditions like cancer, chronic pain, and brain disorders. While this review didn't test melatonin directly, it reveals that the scientific community considers melatonin a promising treatment option worthy of continued research. For patients considering natural approaches to insomnia, this suggests melatonin has an established research foundation, though it's important to understand it works by supporting your body's natural sleep rhythm rather than forcing sleep like some medications. If you're struggling with insomnia and interested in exploring complementary approaches like acupuncture alongside or instead of melatonin, consult with a qualified, licensed acupuncturist who can develop an individualized treatment plan.

This bibliometric analysis examined global research trends in melatonin therapy for insomnia by analyzing 1,084 peer-reviewed publications from 2015-2024 using Web of Science and PubMed databases. Visualization software (VOSviewer and Citespace) mapped collaborative networks, citation patterns, and thematic evolution. Research output demonstrated an overall upward trend despite annual variations, with the United States and Harvard Medical School leading publication volume. Key findings indicate melatonin research has concentrated on three primary populations: pediatric patients, geriatric populations, and individuals with neurological disorders. Emerging research trends show convergence with comorbid conditions including neurological disorders, oncology, and chronic pain management. The analysis identifies Bruni O. as the most prolific author and Morin C.M. with highest co-citation frequency, with Gringas P. (2017) being the most-cited reference. Clinical takeaway: The growing research base supports melatonin as an evidence-informed option for insomnia, particularly in populations with circadian rhythm disruption or comorbid neurological conditions, warranting consideration in integrative treatment protocols.